We want to transform healthcare by developing novel immunotherapies that are lifesaving and improving quality of life around the world.
We are a clinical-stage biotechnology company listed on NASDAQ First North Growth Market Sweden with a resolute vision of the future:
Developing innovative immunotherapies for a healthier world
Advancing groundbreaking immunotherapies through our exclusive technological platform
By leveraging our proprietary ExpreS2 protein expression system, we are playing a key role in the development of cutting-edge immunotherapies to address some of the worst and most impactful diseases.
Our immunotherapy candidates aim at bringing hope to millions by treating cancer and preventing infectious diseases, saving lives, and fostering resilient communities.
ES2B-C001: Advancing HER2 Cancer Immunotherapy
At ExpreS2ion Biotech, we are developing ES2B-C001, an active immunotherapy candidate designed to address HER2-expressing cancers. ES2B-C001 combines HER2 antigens produced using ExpreS2ion’s proprietary ExpreS2 platform with a virus-like particle delivery system, with the aim of stimulating a broad and durable antibody response.
ES2B-C001 is designed to target all four extracellular domains of the HER2 receptor, distinguishing it from HER2-targeting approaches such as monoclonal antibodies and antibody-drug conjugates that typically bind to a single extracellular domain. This multi-domain approach is being evaluated in an ongoing Phase I clinical trial, where ExpreS2ion is assessing safety, immunogenicity, translational markers, and preliminary signals of clinical activity.
Watch the video below to learn more about this breakthrough approach.
Latest news
Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN
Hørsholm, Denmark, 20 January 2026 – ExpreS2ion Biotech Holding AB’s today announces that, effective today, 20 January 2026, the Company will transition its press release distribution from Cision to MFN (Modular Finance News). Subscribers who wish to continue receiving the Company’s press releases must register on the MFN platform. This change is part of the…
Read moreExpreS2ion to Participate in Key Investor Event in January 2026
Hørsholm, Denmark, 19 January 2026 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in an upcoming investor event in January 2026, the Redeye Thematic Event: Fight Cancer.
Read moreExpreS2ion Reports Updated Immunogenicity Data from First Three Patients and DSMB Recommendation to Progress ES2B-C001 Phase I Trial to Next Dose Cohort
Hørsholm, Denmark, 19 December 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today reports (i) updated immunogenicity results from the first three patients enrolled in its ongoing Phase I clinical trial of ES2B-C001, a novel HER2-targeted…
Read more